Literature DB >> 34968746

Mumps virus-specific immune response outcomes and sex-based differences in a cohort of healthy adolescents.

Marguerite M Riggenbach1, Iana H Haralambieva1, Inna G Ovsyannikova1, Daniel J Schaid2, Gregory A Poland1, Richard B Kennedy3.   

Abstract

Despite high levels of MMR-II usage in the US, mumps outbreaks continue to occur. Evidence suggests that mumps vaccine-induced humoral immunity wanes over time. Relatively few studies have examined cell-mediated immunity or reported on sex-based differences. To better understand sex-based differences in the immune response to mumps vaccine, we measured neutralizing antibody titers and mumps-specific cytokine/chemokine responses in a cohort of 748 adolescents and young adults after two doses of MMR vaccine. We observed significantly higher neutralizing antibody titers in females than in males (120.8 IU/mL, 98.7 IU/mL, p = 0.038) but significantly higher secretion levels of MIP-1α, MIP-1β, TNFα, IL-6, IFNγ, and IL-1β in males compared to females. These data demonstrate that sex influences mumps-specific humoral and cell-mediated immune response outcomes, a phenomenon that should be considered during efforts to improve vaccines and prevent future outbreaks.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cellular immunity; Chemokine; Cytokine; MMR vaccine; Mumps; Sex-based differences

Mesh:

Substances:

Year:  2021        PMID: 34968746      PMCID: PMC8760162          DOI: 10.1016/j.clim.2021.108912

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  57 in total

1.  Mumps outbreaks in highly vaccinated populations: What makes good even better?

Authors:  Corinne Vandermeulen; Geert Leroux-Roels; Karel Hoppenbrouwers
Journal:  Hum Vaccin       Date:  2009-07-27

Review 2.  Sex-based differences in immune function and responses to vaccination.

Authors:  Sabra L Klein; Ian Marriott; Eleanor N Fish
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-01       Impact factor: 2.184

3.  Vaccine waning and mumps re-emergence in the United States.

Authors:  Joseph A Lewnard; Yonatan H Grad
Journal:  Sci Transl Med       Date:  2018-03-21       Impact factor: 17.956

4.  Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response.

Authors:  T Nakayama; T Urano; M Osano; M Nakagawa; N Maehara; K Sasaki; A M Yamamura; S Makino
Journal:  Microbiol Immunol       Date:  1990       Impact factor: 1.955

5.  Rubella elimination programme strengthened through measles elimination programme in Catalonia.

Authors:  Angela Domínguez; Nuria Torner; Ana Martínez; Josep Costa; Pere Plans; Pilar Ciruela; Lluís Salleras
Journal:  Vaccine       Date:  2005-09-26       Impact factor: 3.641

6.  Genetic polymorphisms associated with rubella virus-specific cellular immunity following MMR vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Nathaniel D Lambert; V Shane Pankratz; Gregory A Poland
Journal:  Hum Genet       Date:  2014-08-07       Impact factor: 4.132

7.  Durability of humoral immune responses to rubella following MMR vaccination.

Authors:  Stephen N Crooke; Marguerite M Riggenbach; Inna G Ovsyannikova; Nathaniel D Warner; Min-Hsin Chen; Lijuan Hao; Joseph P Icenogle; Gregory A Poland; Richard B Kennedy
Journal:  Vaccine       Date:  2020-11-12       Impact factor: 3.641

8.  Mumps outbreak in Orthodox Jewish communities in the United States.

Authors:  Albert E Barskey; Cynthia Schulte; Jennifer B Rosen; Elizabeth F Handschur; Elizabeth Rausch-Phung; Margaret K Doll; Kisha P Cummings; E Oscar Alleyne; Patricia High; Jacqueline Lawler; Andria Apostolou; Debra Blog; Christopher M Zimmerman; Barbara Montana; Rafael Harpaz; Carole J Hickman; Paul A Rota; Jennifer S Rota; William J Bellini; Kathleen M Gallagher
Journal:  N Engl J Med       Date:  2012-11-01       Impact factor: 91.245

Review 9.  The Xs and Y of immune responses to viral vaccines.

Authors:  Sabra L Klein; Anne Jedlicka; Andrew Pekosz
Journal:  Lancet Infect Dis       Date:  2010-05       Impact factor: 71.421

10.  Isolation of mumps virus from human beings with induced apparent or inapparent infections.

Authors:  G HENLE; W HENLE
Journal:  J Exp Med       Date:  1948-08       Impact factor: 14.307

View more
  2 in total

1.  Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine.

Authors:  Huy Quang Quach; Inna G Ovsyannikova; Gregory A Poland; Richard B Kennedy
Journal:  Sci Rep       Date:  2022-09-13       Impact factor: 4.996

2.  Clinical efficacy evaluation and potential mechanism prediction on Pudilan Xiaoyan oral liquid in treatment of mumps in children based on meta-analysis, network pharmacology, and molecular docking.

Authors:  Yi Liu; Xin Cui; Junyu Xi; Yanming Xie
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.